Abstract
This review examines the extent of the increased rate of heart failure (HF) in the diabetic patient, along with the possible causes for this increase and the poor prognosis associated with HF. Also reviewed are the therapies that are available for the treatment of diabetic HF and whether intensifying the use of these therapies might improve the worsened clinical outcomes for the patient who has diabetes.
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Animals
-
Autonomic Nervous System / physiopathology
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetes Mellitus, Type 2 / epidemiology
-
Diabetes Mellitus, Type 2 / physiopathology
-
Diabetic Angiopathies / drug therapy
-
Diabetic Angiopathies / epidemiology*
-
Diabetic Angiopathies / physiopathology
-
Diabetic Retinopathy / epidemiology
-
Diabetic Retinopathy / physiopathology
-
Drug Therapy, Combination
-
Heart Failure / epidemiology*
-
Heart Failure / physiopathology
-
Humans
-
Hyperglycemia / epidemiology
-
Hyperglycemia / physiopathology
-
Hyperlipidemias / epidemiology
-
Hyperlipidemias / physiopathology
-
Insulin Resistance / physiology
-
Mineralocorticoid Receptor Antagonists / pharmacology
-
Mineralocorticoid Receptor Antagonists / therapeutic use
-
Prognosis
-
Renin-Angiotensin System / genetics
-
Renin-Angiotensin System / physiology
-
Stroke Volume
-
Thiazolidinediones / pharmacology
-
Thiazolidinediones / therapeutic use
-
Ventricular Dysfunction, Left / epidemiology
-
Ventricular Dysfunction, Left / physiopathology
Substances
-
Adrenergic beta-Antagonists
-
Mineralocorticoid Receptor Antagonists
-
Thiazolidinediones